Succinylcholine Chloride

CHEMBL983 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
361.3 g/mol
LogP
Phase
4

Succinylcholine chloride is a depolarizing neuromuscular blocking agent used for rapid sequence intubation and tracheal intubation as an adjunct to anesthesia, acting as a nicotinic acetylcholine receptor agonist that causes sustained depolarization of the motor end plate, resulting in initial fasciculations followed by flaccid paralysis. Its extremely rapid onset (60 seconds) and short duration (10-15 minutes) due to hydrolysis by plasma cholinesterase make it the agent of choice for emergency intubation. It must be used with great caution in patients with hyperkalemia risk.

Molekularmasse

361,3000 g/mol

TPSA

52,60 Ų

Therapeutische Bereiche

Wirkmechanismus

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]

InChI

InChI=1S/C14H30N2O4.2ClH/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6;;/h7-12H2,1-6H3;2*1H/q+2;;/p-2

Molecular Formula

C14H30Cl2N2O4

HBD / HBA

- / 6

Rotierbare Bindungen

11

Schwere Atome

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Succinylcholine chloride is a depolarizing neuromuscular blocking agent used for rapid sequence intubation and tracheal intubation as an adjunct to anesthesia, acting as a nicotinic acetylcholine receptor agonist that causes sustained depolarization of the motor end plate, resulting in initial fasciculations followed by flaccid paralysis. Its extremely rapid onset (60 seconds) and short duration (10-15 minutes) due to hydrolysis by plasma cholinesterase make it the agent of choice for emergency intubation. It must be used with great caution in patients …

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Yes, Succinylcholine Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL983. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 22475. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.